Sold as Vyleesi, bremelanotide was approved in 2019 for premenopausal women with acquired, generalised HSDD clinically defined as low sexual desire causing significant personal distress
I go, I need it right away
Health & Safety, Sharps & Infection Control Training In-depth guidance on working safely with sharps, waste disposal, hygiene standards, PPE, anaphylaxis awareness and legal responsibilities when delivering injectable treatments
In terms of human research, one small 2024 study gave BPC-157 injections (10mg total) to 12 women with interstitial cystitis
BPC-157 Strength: 10 mg Body Protecting Compound-157 A stronger mid-tier option for patients discussing more targeted support with their provider
Supports vascularity and blood flow: Enhances blood circulation to injured areas, ensuring efficient delivery of nutrients and oxygen for faster recovery